PTEN公司
PI3K/AKT/mTOR通路
张力素
癌症研究
蛋白激酶B
癌变
抑癌基因
癌症
医学
RPTOR公司
西罗莫司
生物
信号转导
内科学
细胞生物学
作者
Conghui Zhu,Shuangqing Peng,Lili Cui,Wanying Cao,Lishi Zhang,Zengming Zhao,Jia Li,Tingfen Zhang,Jiabin Guo,Chengfang Pang
出处
期刊:Gastric Cancer
[Springer Nature]
日期:2021-08-09
卷期号:25 (1): 96-106
被引量:5
标识
DOI:10.1007/s10120-021-01229-x
摘要
The tumor suppressor gene phosphatase and tensin homolog (PTEN) in PI3K/Akt/mTOR pathway is essential in inhibiting tumor growth and metastasis. However, whether the mutation of PTEN gene could induce tumorigenesis and impact the treatment of gastric cancer is still unclear. The purpose of the study was to investigate the combined treatment of gastric tumorigenesis using Rapamycin and Fluorouracil (5-Fu) through interfering with the Akt/mTOR pathway in a mouse model with PTEN conditional deletion. Three groups of mice were exposed for 5 days to Rapamycin and 5-Fu separately and together. The gene expression of the Akt/mTOR pathway, the protein expression of caspase-3 and p-Akt, p-S6K and p-4EBP1, and the pathological changes in stomachs were analyzed. Our study demonstrates that the conditional PTEN deletion in the cells of glandular stomach induces hyperplastic gastric tumors in mice. The combined Rapamycin administration with 5-Fu resulted in better outcomes than their separate administration for the treatment of gastric cancer by inhibiting the mTOR signal pathway. Our study indicates that Rapamycin has a synergistic interaction with chemotherapeutic 5-Fu, and demonstrates a potential therapeutic combination treatment on glandular stomach tumor with PTEN functional absence or aberrantly activated Akt/mTOR pathway. It provides important insights into the inhibition of the Akt/mTOR pathway in gastric cancer clinical therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI